Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M

Compass Therapeutics, Inc.

Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.
Cash and marketable securities $135M as of Sep 30, 2024; runway into Q1 2027.
Phase 2/3 CTX-009 BTC trial fully enrolled; top-line data expected end of Q1 2025.
CTX-009 Phase 2 in DLL4-positive CRC second-line planned for mid-2025.
CTX-471 Phase 2 trial in NCAM-expressing tumors planned for mid-2025 based on biomarker data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.